2-[2-[4-[2-(3-hydroxy-6-oxo-xanthen-9-yl)benzoyl]piperazin-1-yl]-2-oxo-ethoxy]acetic acid | 1251849-04-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 2-[2-[4-[2-(3-hydroxy-6-oxo-xanthen-9-yl)benzoyl]piperazin-1-yl]-2-oxo-ethoxy]acetic acid
• 英文别名: 2-[2-[4-[2-(3-hydroxy-6-oxoxanthen-9-yl)benzoyl]piperazin-1-yl]-2-oxoethoxy]acetic acid
• CAS: 1251849-04-3
• 化学式: C₂₈H₂₄N₂O₈
• 分子量: 516.507
• InChiKey: YKTYUAKVPASAPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  6-hydroxy-9-[2-(piperazine-1-carbonyl)phenyl]xanthen-3-one hydrochloride 、 碳酸氢钠 、 二甘醇酐 、 盐酸 、 氯化钠 在 二氯甲烷 、 Sodium sulfate-III 作用下， 以 Brine 、 二氯甲烷 、 四氢呋喃 为溶剂， 反应 23.17h， 生成 2-[2-[4-[2-(3-hydroxy-6-oxo-xanthen-9-yl)benzoyl]piperazin-1-yl]-2-oxo-ethoxy]acetic acid
  参考文献：
  名称：

  Targeted Delivery of Factor VIII Proteins to Platelets

  摘要：

  本发明涉及一种新型分子和多肽，其中至少包含一个与人类凝血因子VIII具有重要同源性（同源性）或生物活性部分的氨基酸序列，相关分子（如编码这种多肽的核酸），包括这种多肽的组成物（如制药配方），以及制备和使用这种多肽的方法。

  公开号：

  US20160251409A1

文献信息

• TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS
  申请人：Østergaard Henrik

  公开号：US20120093840A1

  公开（公告）日：2012-04-19

  The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.

  本发明涉及新型分子和多肽，包括至少具有与人体因子VIII或其生物活性部分显著同源性（同源性）的氨基酸序列的多肽，相关分子（如编码这些多肽的核酸），包含这些多肽的组合物（如制药配方），以及制备和使用这些多肽的方法。
• Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets
  申请人：Novo Nordisk A/S

  公开号：US11135275B2

  公开（公告）日：2021-10-05

  Described are procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing procoagulant proteins; polynucleotides that encode fusion proteins and cells that expresses them. Furthermore, described are procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with such procoagulant proteins.

  描述的是促凝血蛋白，例如可以是融合蛋白或化学共轭物；生产促凝血蛋白的方法；编码融合蛋白的多核苷酸和表达融合蛋白的细胞。此外，还介绍了可用作药物的促凝血蛋白。患有凝血病的人，如血友病 A 和血友病 B，无论有无抑制剂，均可使用此类促凝血蛋白进行治疗。
• COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS
  申请人：Novo Nordisk Health Care AG

  公开号：EP2680875B1

  公开（公告）日：2019-10-23
• Coagulation Factor-Targeting to TLT-1 on Activated Platelets
  申请人：Novo Nordisk A/S

  公开号：US20160263230A1

  公开（公告）日：2016-09-15

  The current invention relates to: procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing said procoagulant proteins; polynucleotides that encode said fusion proteins and cells that expresses them. Furthermore, the current invention relates to procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with the procoagulant proteins of the current invention.
• Coagulation factor-targeting to TLT-1 on activated platelets
  申请人：Novo Nordisk A/S

  公开号：US20190083587A1

  公开（公告）日：2019-03-21

  The current invention relates to: procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing said procoagulant proteins; polynucleotides that encode said fusion proteins and cells that expresses them. Furthermore, the current invention relates to procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with the procoagulant proteins of the current invention.